Yamaguchi University | Date: 2016-10-14
The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis. The therapeutic agent is also useful as a therapeutic agent for corneal scarring and conjunctival scarring both associated with keratoconjunctive disorders.
Yamaguchi University | Date: 2015-04-22
An object is to provide a thermotolerant yeast capable of assimilating xylose to produce ethanol or a mutant strain thereof and a method for producing ethanol by assimilation of xylose. There is used a yeast, Kluyveromyces marxianus strain No. 21 (accession number: NITE BP-01739), or a mutant strain thereof that has xylose assimilation ability and ethanol production ability when cultured at 30 C. under aerobic conditions using a culture medium containing xylose as a sugar source. Also performed is a method for producing ethanol, comprising culturing the yeast or the mutant strain thereof under aerobic conditions using a culture medium containing xylose as a sugar source.
Daicel Corporation and Yamaguchi University | Date: 2017-03-22
The present invention provides a compound that thickens or gels a fluid organic substance to a desired viscosity or homogeneously stabilizes a composition containing a fluid organic substance, a thickening/stabilizing agent containing the compound, a thickened/stabilized composition containing the thickening/stabilizing agent and a fluid organic substance, and a method for producing a thickened/stabilized composition. The compound of the present invention is represented by the following formula (1). In the formula, R^(1) and R^(2) are different from each other and represent an aliphatic hydrocarbon group having not less than 4 carbon atoms, and n represents an integer of 1 to 3. The thickening/stabilizing agent of the present invention contains the compound.
Yamaguchi University | Date: 2015-07-01
A plurality of branch bars is provided on opposing sides of paired strut pieces connected by links in a strut to protrude from one towards the other side, and a plurality of ratchet teeth is formed on the side of the branch bars respectively. When a stent made of polymer material having a cylindrical constitution in which a plurality of struts is connected by links is deformed to enlarge its diameter, the paired struts are deformed to come near to each other, so that the branch bars overlap each other with the ratchet teeth formed thereon engaging with each other. As the effect of engagement of the ratchet teeth with each other, while deformation of the struts so as to enlarge the diameter of the stent is allowed, deformation so as to reduce the diameter of the stent is inhibited.
Daicel Corporation and Yamaguchi University | Date: 2015-07-07
Provided is a compound that thickens and/or gelatinizes a fluid organic substance to a desired viscosity, or uniformly stabilizes a composition containing the fluid organic substance. Also provided are: a thickening/stabilizing agent including the compound, a thickened/stabilized composition including the thickening/stabilizing agent and a fluid organic substance, and a method for producing the composition. The compound according to the present invention is represented by Formula (1): (R^(2)HNOC)_(4-n)R^(1)(CONHR^(3))_(n)(1) where R^(1 )is a group resulting from removing four hydrogen atoms from the structural formula of an aromatic hydrocarbon or cyclohexane; R^(2 )is, independently in each occurrence, an aliphatic hydrocarbon group containing 1 to 4 carbon atoms; R^(3 )is, independently in each occurrence, an aliphatic hydrocarbon group containing 6 or more carbon atoms; and n is an integer of 1 to 3.
Daicel Corporation and Yamaguchi University | Date: 2017-05-17
Provided is a compound that thickens and/or gelatinizes a fluid organic substance to a desired viscosity, or uniformly stabilizes a composition containing the fluid organic substance. Also provided are: a thickening/stabilizing agent including the compound, a thickened/stabilized composition including the thickening/stabilizing agent and a fluid organic substance, and a method for producing the composition. The compound according to the present invention is represented by Formula (1):(R^(2)-HNOC)_(4-n)-R^(1)-(CONH-R^(3))_(n)(1)where R^(1) is a group resulting from removing four hydrogen atoms from the structural formula of an aromatic hydrocarbon or cyclohexane; R^(2) is, independently in each occurrence, an aliphatic hydrocarbon group containing 1 to 4 carbon atoms; R^(3) is, independently in each occurrence, an aliphatic hydrocarbon group containing 6 or more carbon atoms; and n is an integer of 1 to 3.
Song Y.-F.,Beijing University of Chemical Technology |
Tsunashima R.,Yamaguchi University
Chemical Society Reviews | Year: 2012
Polyoxometalates (POMs) are a subset of metal oxides with unique physical and chemical properties, which can be reliably modified through various techniques and methods to develop sophisticated materials and devices. In parallel with the large number of new crystal structures reported in the literature, the application of these POMs towards multifunctional materials has attracted considerable attention. This critical review summarizes recent progress on POM-based molecular and composite materials, and particularly highlights the emerging areas that are closely related to surface, electronic, energy, environment, life science, etc. (171 references). © The Royal Society of Chemistry 2012.
Chugoku Electric Power Co. and Yamaguchi University | Date: 2016-02-03
The present invention is a plasma spraying apparatus (100a) including: a main torch (1) that includes a first electrode (3) having a spraying material discharge hole, a first mantle (4), and a first insulator (27) having a first plasma gas introducing port (5); and an auxiliary torch (2) that includes a second electrode (10), a second mantle (11), and a second insulator (28) having a second plasma gas introducing port (12). In this plasma spraying apparatus, a spraying material (20) supplied from the spraying material discharge hole is melted at the axial center of plasma (18) that is formed on the central axis of the first electrode (3) by the first electrode (3) and the second electrode (10), and a gas introducing part (4c) that introduces gas is provided on an inlet side of an opening part (4a) and/or in a tapered part (4b) provided between the opening part (4a) and the first insulator (27) in the first mantle (4). With this configuration, it is possible to prevent the spray material (20) from adhering to an inner wall of the opening part (4a).
Kimura K.,Yamaguchi University
Investigative ophthalmology & visual science | Year: 2013
TNF-α disrupts the barrier function of cultured human corneal epithelial (HCE) cells. We investigated the effects of the cytoprotective drug rebamipide on this barrier disruption by TNF-α as well as on corneal epithelial damage in a rat model of dry eye. The barrier function of HCE cells was evaluated by measurement of transepithelial electrical resistance. The distribution of tight-junction (ZO-1, occludin) and adherens-junction (E-cadherin, β-catenin) proteins, and the p65 subunit of nuclear factor-κB (NF-κB) was determined by immunofluorescence microscopy. Expression of junctional proteins as well as phosphorylation of the NF-κB inhibitor IκB-α and myosin light chain (MLC) were examined by immunoblot analysis. A rat model of dry eye was developed by surgical removal of exorbital lacrimal glands. Rebamipide inhibited the disruption of barrier function as well as the downregulation of ZO-1 expression, and the disappearance of ZO-1 from the interfaces of neighboring HCE cells induced by TNF-α. It also inhibited the phosphorylation and downregulation of IκB-α, the translocation of p65 to the nucleus, the formation of actin stress fibers, and the phosphorylation of MLC induced by TNF-α in HCE cells. Treatment with rebamipide eyedrops promoted the healing of corneal epithelial defects as well as attenuated the loss of ZO-1 from the surface of corneal epithelial cells in rats. Rebamipide protects corneal epithelial cells from the TNF-α-induced disruption of barrier function by maintaining the distribution and expression of ZO-1 as well as the organization of the actin cytoskeleton. Rebamipide is, thus, a potential drug for preventing or ameliorating the loss of corneal epithelial barrier function associated with ocular inflammation.
Kanda T.,Yamaguchi University
Journal of Neurology, Neurosurgery and Psychiatry | Year: 2013
The blood-nerve barrier (BNB) is a dynamic and competent interface between the endoneurial microenvironment and the surrounding extracellular space or blood. It is localised at the innermost layer of the multilayered ensheathing perineurium and endoneurial microvessels, and is the key structure that controls the internal milieu of the peripheral nerve parenchyma. Since the endoneurial BNB is the point of entry for pathogenic T cells and various soluble factors, including cytokines, chemokines and immunoglobulins, understanding this structure is important to prevent and treat human immune mediated neuropathies such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) syndrome and a subset of diabetic neuropathy. However, compared with the blood-brain barrier, only limited knowledge has been accumulated regarding the function, cell biology and clinical significance of the BNB. This review describes the basic structure and functions of the endoneurial BNB, provides an update of the biology of the cells comprising the BNB, and highlights the pathology and pathomechanisms of BNB breakdown in immune mediated neuropathies. The human immortalised cell lines of BNB origin established in our laboratory will facilitate the future development of BNB research. Potential therapeutic strategies for immune mediated neuropathies manipulating the BNB are also discussed.